Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05256654 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3561774 in Participants With Mixed Dyslipidemia
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
NCT05256654 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 205 participants.
The verdict
NCT05256654, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
Study Summary
This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses in participants with mixed dyslipidemia and on a stable dose of a statin.
Interventions
- DRUG Placebo
- DRUG LY3561774
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2022-07-20 |
| Est. Completion | 2024-05-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05256654
The ClinicalTrials.gov registry entry for NCT05256654 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05256654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05256654 about?
NCT05256654 is a clinical study titled "A Study of LY3561774 in Participants With Mixed Dyslipidemia". This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses in participants with mixed dyslipidemia and on a stable dose of a statin.
What is the current status of trial NCT05256654?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2022-07-20. Estimated completion is 2024-05-23.
What interventions are being tested in trial NCT05256654?
The interventions under investigation include: Placebo (DRUG), LY3561774 (DRUG).
Who is sponsoring clinical trial NCT05256654?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.